Bisacodyl
Halflytely (bisacodyl) is a small molecule pharmaceutical. Bisacodyl was first approved as Halflytely on 2010-07-16. It is used to treat constipation in the USA.
Download report
Favorite
Top OTC Drugs
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bisacodyl
+
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HALFLYTELY | Braintree Laboratories | N-021551 DISCN | 2010-07-16 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gentle laxative | OTC monograph not final | 2023-06-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| constipation | HP_0002019 | D003248 | K59.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | 1 | — | 1 | 2 | |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | 1 | — | — | 1 | |
| Treatment outcome | D016896 | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | 1 | ||
| Encopresis | D004688 | F98.1 | — | — | — | — | 1 | 1 | |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | — | 1 | 1 |
| Polyps | D011127 | EFO_0000662 | — | — | — | — | 1 | 1 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Colonic polyps | D003111 | K63.5 | — | — | — | — | 1 | 1 | |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 1 | 1 |
| Gastric outlet obstruction | D017219 | EFO_1000947 | — | — | — | — | 1 | 1 | |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BISACODYL |
| INN | bisacodyl |
| Description | Bisacodyl is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 603-50-9 |
| RxCUI | 1596 |
| ChEMBL ID | CHEMBL942 |
| ChEBI ID | — |
| PubChem CID | 2391 |
| DrugBank | DB09020 |
| UNII ID | 10X0709Y6I (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,065 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
703 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more